Filer Snapshot

Aquilo Capital Management, LLC

CIK 0001591986. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

32

Latest filing

12 Nov 2025

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2025. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Largest parsed holding

BPMC

$7.43M reported value

Open holding

13D/G large stake

DTIL

30 Jun 2025 · 0% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Source: SEC Form 13F

13F-HR filed on 12 Nov 2025 for CIK 0001591986.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$4.34M

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$4.34M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

SPRO

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

DTIL
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
One Letterman Drive, Suite D4900, Building D, San Francisco, CA, 94129
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
CA
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Aquilo Capital Management, LLC

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Quick read

  • Latest parsed 13F shows $37.08M across 12 reported holdings for Q1 2025.
  • Largest parsed 13F holding: BPMC at $7.43M.
  • 1 recent 13D/G stake row found; top row is DTIL at 0% ownership.
  • Forms 3/4/5 show insider context for SPRO worth $4.34M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 12 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 1 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2025 - 15 May 2025

Top 5 concentration

69%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$25.64M

Compared with $37.08M total 13F value.

Top 5 net change

-$6.13M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: ZYME · Largest trim: BPMC

BPMC ARWR PTGX KYMR DTIL Other holdings

BPMC

20%

Blueprint Medicines Corp

$7.43M

ARWR

18.9%

Arrowhead Pharmaceuticals In

$7.01M

PTGX

10.7%

Protagonist Therapeutics Inc

$3.95M

KYMR

10.2%

Kymera Therapeutics Inc

$3.79M

DTIL

9.3%

Precision Biosciences Inc

$3.46M

13D/G large-stake context

DTIL

30 Jun 2025 · Common Stock, par value $0.000005 per share

0%

Forms 3/4/5 insider context

SPRO

22 Sep 2022 · 10% owner

$4.34M

Latest update

What changed recently for Aquilo Capital Management, LLC

New filing available

Latest 13F period: Q3 2025. Open the source-backed page to inspect the fresh filing or facts context.

Update date

12 Nov 2025

Page type

Filer profile

Latest period

Q3 2025

Institutional portfolio context was refreshed from a 13F filing filed on 12 Nov 2025.

Benchmark Context

Benchmark context for this company

Aquilo Capital Management, LLC has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q3 2025. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

SEC filing record

CIK 0001591986 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
32
First seen
14 Aug 2018
Latest filing
12 Nov 2025
Entity
Company

Latest Filings

Showing the latest 12 of 32 SEC filings for Aquilo Capital Management, LLC.

13F-HR

13F-HR filing

Filing date
12 Nov 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
06 Aug 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
06 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Nov 2024
Reporting date
30 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Aug 2024
Reporting date
30 Jun 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2024
Reporting date
31 Mar 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Feb 2024
Reporting date
31 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Nov 2023
Reporting date
30 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Aug 2023
Reporting date
30 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .